Celgene prevails in Apotex and Cipla IPR challenges of Abraxane® patents
Clients Celgene Corporation
Jones Day served as lead counsel and successfully defended Celgene Corporation in connection with six inter partes review (IPR) petitions filed by Apotex or Cipla against U.S. Patent Nos. 8,138,229, 7,820,788, and 7,923,536, which are related to formulations for Celgene's chemotherapeutic drug marketed as Abraxane®. Following the filing of the Patent Owner's Preliminary Response by Celgene, the Patent Trial and Appeal Board (PTAB) denied institution of all six IPR petitions with regard to all of the challenged claims.
Apotex Inc., et al. v. Abraxis Bioscience, LLC, et al., IPR Nos. 2018-00151, -00152, -00153 (PTAB); Cipla Limited, et al. v. Abraxis Bioscience, LLC, et al., IPR Nos. 2018-00162, -00163, -00164 (PTAB)